CYTK Cytokinetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CYTK

Price (delayed)

$34.53

Market cap

$3.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.33

Enterprise value

$3.97B

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by ...

Highlights
Cytokinetics's gross profit has decreased by 36% from the previous quarter but it has increased by 34% YoY
The revenue has declined by 36% since the previous quarter but it has increased by 34% year-on-year
The debt has soared by 178% YoY
CYTK's equity has dropped by 144% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cytokinetics.com
Peers: ABIO LGND TRVN ACOR

Key stats

What are the main financial stats of CYTK
Market
Shares outstanding
95.16M
Market cap
$3.29B
Enterprise value
$3.97B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
32.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.97
Earnings
Revenue
$94.59M
EBIT
-$369.54M
EBITDA
-$363.73M
Free cash flow
-$310.85M
Per share
EPS
-$4.33
Free cash flow per share
-$3.46
Book value per share
-$1.14
Revenue per share
$1.05
TBVPS
$11.3
Balance sheet
Total assets
$1.01B
Total liabilities
$1.12B
Debt
$749.34M
Equity
-$107.9M
Working capital
$710.57M
Liquidity
Debt to equity
-6.94
Current ratio
9.4
Quick ratio
9.25
Net debt/EBITDA
-1.88
Margins
EBITDA margin
-384.5%
Gross margin
100%
Net margin
-411.2%
Operating margin
-342.8%
Efficiency
Return on assets
-41.8%
Return on equity
-1,498.9%
Return on invested capital
-28.5%
Return on capital employed
-39.7%
Return on sales
-390.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CYTK stock price

How has the Cytokinetics stock price performed over time
Intraday
3.51%
1 week
-1.9%
1 month
-19.66%
1 year
-5.32%
YTD
-24.64%
QTD
-24.64%

Financial performance

How have Cytokinetics's revenue and profit performed over time
Revenue
$94.59M
Gross profit
$94.59M
Operating income
-$324.2M
Net income
-$388.96M
Gross margin
100%
Net margin
-411.2%
Cytokinetics's operating margin has plunged by 132% from the previous quarter and by 30% YoY
The net margin has plunged by 116% from the previous quarter and by 35% YoY
The net income has dropped by 81% year-on-year and by 38% since the previous quarter
Cytokinetics's operating income has plunged by 74% YoY and by 48% from the previous quarter

Growth

What is Cytokinetics's growth rate over time

Valuation

What is Cytokinetics stock price valuation
P/E
N/A
P/B
N/A
P/S
32.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
41.97
The EPS has plunged by 55% YoY and by 39% from the previous quarter
CYTK's equity has dropped by 144% year-on-year
The revenue has declined by 36% since the previous quarter but it has increased by 34% year-on-year
CYTK's P/S is 9% below its last 4 quarters average of 36.1 and 7% below its 5-year quarterly average of 35.1

Efficiency

How efficient is Cytokinetics business performance
The ROS has plunged by 118% from the previous quarter and by 38% YoY
The company's return on assets fell by 37% YoY and by 31% QoQ
CYTK's return on invested capital is down by 20% since the previous quarter and by 18% year-on-year

Dividends

What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CYTK.

Financial health

How did Cytokinetics financials performed over time
The total assets is 10% smaller than the total liabilities
Cytokinetics's total liabilities has soared by 88% YoY and by 2.8% from the previous quarter
Cytokinetics's quick ratio has increased by 27% YoY but it has decreased by 19% from the previous quarter
The debt has soared by 178% YoY
CYTK's equity has dropped by 144% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.